160
Participants
Start Date
March 11, 2024
Primary Completion Date
May 31, 2029
Study Completion Date
June 30, 2029
Carbetocin
Carbetocin nasal spray 3.2 mg three times daily (TID)
Maimonides Medical Center, Brooklyn
UPMC-Children's Hospital Pittsburgh, Pittsburgh
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Regional Universitario de Málaga, Málaga
Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital des Enfants, Toulouse
Children's of Alabama, Birmingham
Vanderbilt Clinical Research Center, Nashville
Nationwide Children's Hospital, Columbus
Universitätsklinikum Essen, Essen
University of Iowa, Iowa City
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
SSM Health/Saint Louis University, St Louis
Children's Mercy Kansas City, Kansas City
Christus Children's, San Antonio
Cook Children's Health Care System, Fort Worth
Children's Hospital Colorado, Aurora
University of Utah, Salt Lake City
Phoenix Children's Hospital, Phoenix
KJF Klinik Josefinum gGmbH, Augsburg
Rady Children's Hospital San Diego, San Diego
University of California Irvine, Orange
Stanford University School of Medicine, Palo Alto
Seattle Children's Hospital, Seattle
Boston Children's Hospital, Boston
Alberta Diabetes Institute, Edmonton
CHU Sainte-Justine, Montreal
Parc Taulí Hospital Universitari, Barcelona
University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital, Birmingham
Royal Hospital for Children Glasgow Clinical, Glasgow
Barts Health NHS Trust - The Royal London Hospital, London
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY